Entity Address City Or Town Entity Address, City or Town Fair Value Disclosures [Abstract] Earnings Per Share [Abstract] Fair Value Inputs Level1 [Member] Level 1 [Member] Net Cash Provided By Used In Financing Activities [Abstract] Cash flows from financing activities Amendment Flag Amendment Flag Accrued and other liabilities. Accrued And Other Liabilities Others Document Quarterly Report Document Quarterly Report Milestone achievement two member. Milestone Achievement Two [Member] Achievement of Various Regulatory Approval and Reimbursement-Based Milestones in the United States, Europe and Japan [Member] Statement [Table] Statement [Table] Preferred Stock Shares Outstanding Preferred stock, shares outstanding Preferred Stock, Shares Outstanding, Beginning Balance Preferred Stock, Shares Outstanding, Ending Balance Nature Of Operations Nature of the Business Liabilities And Stockholders Equity Total liabilities and stockholders’ equity Plan Name [Domain] Plan Name First Line Treatment Of Metastatic Adenocarcinoma Of Pancreas [Member] First Line Treatment of Metastatic Adenocarcinoma of Pancreas [Member] Entity Incorporation State Country Code Entity Incorporation, State or Country Code Liabilities Current Total current liabilities Fair Value Measurements Recurring [Member] Recurring Basis [Member] Accounts Payable And Accrued Liabilities Disclosure [Text Block] Accounts Payable, Accrued Expenses and Other Contingent milestone payments receivable. Contingent Milestone Payments Receivable Contingent milestone payments receivable Preferred Stock Shares Authorized Preferred stock, shares authorized Entity Small Business Entity Small Business Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Cash and cash equivalents, end of period Cash and cash equivalents, beginning of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Total Type Of Arrangement [Axis] Collaborative Arrangement and Arrangement Other than Collaborative Assets Current Total current assets Ipsen S.A. Ipsen S A [Member] Ipsen [Member] Net proceeds from sale of in progress research and development asset. Net Proceeds From Sale Of In Progress Research And Development Asset Net proceeds from sale of in process research and development Weighted Average Number Of Shares Outstanding Basic Weighted-average common shares used to compute basic net loss per common share Weighted Average Number of Shares Outstanding, Basic, Total City Area Code City Area Code Repayment received or receivable for expenses incurred on behalf of a client or customer, other than those reimbursements received by landlords from tenants. Reimbursement Revenues Reimbursement of expenses Celator Pharmaceuticals Inc [Member]. Celator Pharmaceuticals Inc [Member] Celator Pharmaceuticals Inc [Member] Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] Liabilities Total liabilities Document Period End Date Document Period End Date Option fee. Option Fee Option fee Fourteener oncology inc member. Fourteener Oncology Inc [Member] 14ner Sale [Member] Range [Axis] Statistical Measurement Cash payment received. Cash Payment Received Cash payment received Assets Total assets Earnings Per Share Diluted Net loss per common share - diluted Earnings Per Share, Diluted, Total Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block] Schedule of Outstanding Options Excluded from Computation of Diluted Loss Per Share Terms of exercise option Terms of Excercise Option Terms of Excercise Option Entity Address Postal Zip Code Entity Address, Postal Zip Code Revenue From Contract With Customer Including Assessed Tax Cumulative worldwide net sales target Document Fiscal Period Focus Document Fiscal Period Focus Preferred stock, $0.01 par value: 10,000 shares authorized at March 31, 2023 and December 31, 2022; no shares issued or outstanding at March 31, 2023 or December 31, 2022 Preferred Stock Value Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total Investment Income Interest Interest income Repurchase Agreement Counterparty Name [Domain] Counterparty Name Net Cash Provided By Used In Financing Activities Net cash provided by financing activities Statement Of Financial Position [Abstract] Entity File Number Entity File Number Scenario Unspecified [Domain] Scenario Statement Of Cash Flows [Abstract] Gain on sale of in progress research and development asset. Gain On Sale Of In Process Research And Development Asset Gain on sale of in-process research and development Range [Member] Statistical Measurement Statement Of Stockholders Equity [Abstract] Legal Entity [Axis] Legal Entity Fair Value Disclosures [Text Block] Fair Value of Financial Instruments Proceeds From Stock Options Exercised Proceeds from exercise of stock options Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis] Antidilutive Securities Preferred Stock Par Or Stated Value Per Share Preferred stock, par value Cash Cash Equivalents And Short Term Investments Cash, cash equivalents and marketable securities Cash, Cash Equivalents, and Short-Term Investments, Total Weighted Average Number Of Diluted Shares Outstanding Weighted-average common shares used to compute diluted net loss per common share Weighted Average Number of Shares Outstanding, Diluted, Total General And Administrative Expense [Member] General and Administrative Expense [Member] Current Fiscal Year End Date Current Fiscal Year End Date Other Assets Noncurrent Other assets Milestone achievement three member. Milestone Achievement Three [Member] Achievement Various Cumulative Worldwide Net Sales Targets Between $100.0 million and $300.0 million for MM-121 and MM-111 [Member] Entity Address Address Line1 Entity Address, Address Line One New Accounting Pronouncements And Changes In Accounting Principles [Text Block] Recent Accounting Pronouncements Preferred Stock Shares Issued Preferred stock, shares issued Fair Value By Fair Value Hierarchy Level [Axis] Level 2 [Member] Operating Income Loss Loss from operations Additional Paid In Capital Common Stock Additional paid-in capital Statement Scenario [Axis] Scenario Entity Filer Category Entity Filer Category Asset purchase option agreement. Asset Purchase Option Agreement [Member] Asset Purchase Option Agreement [Member] Operating Expenses Total operating expenses Entity Current Reporting Status Entity Current Reporting Status Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain] Asset Class Schedule Of Accounts Payable And Accrued Liabilities Table [Text Block] Schedule of Accounts Payable, Accrued Expenses and Other Consideration received. Consideration Received Consideration received Stockholders Equity Balance Balance Total stockholders’ equity Fair Value By Asset Class [Axis] Asset Class Entity Tax Identification Number Entity Tax Identification Number Income Statement Location [Axis] Income Statement Location Common stock, $0.01 par value: 30,000 shares authorized at March 31, 2023 and December 31, 2022; 14,255 and 14,215 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively Common Stock Value Summary of significant accounting policies. Summary Of Significant Accounting Policies [Table] Summary Of Significant Accounting Policies [Table] Retained Earnings Accumulated Deficit Accumulated deficit Accumulated deficit Retained Earnings (Accumulated Deficit), Total Statement Equity Components [Axis] Equity Components Increase Decrease In Accounts Payable And Accrued Liabilities Accounts payable, accrued expenses and other Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total Consideration receivable. Consideration Receivable Consideration receivable Entity Emerging Growth Company Entity Emerging Growth Company Operating Expenses [Abstract] Operating expenses: Gain loss on payment of consideration. Gain Loss On Payment Of Consideration Gain related to payment of consideration Document Transition Report Document Transition Report Nonoperating Income Expense Total other income Entity Common Stock Shares Outstanding Entity Common Stock, Shares Outstanding After Failure Of First Line Chemotherapy [Member] After Failure of First Line Chemotherapy [Member] Additional Paid In Capital [Member] Additional Paid-In Capital [Member] Arrangements And Nonarrangement Transactions [Member] Collaborative Arrangement and Arrangement Other than Collaborative Entity Registrant Name Entity Registrant Name Liabilities Fair Value Disclosure Liabilities measured at fair value Liabilities, Fair Value Disclosure, Total Cash And Cash Equivalents At Carrying Value Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value, Total Earnings Per Share [Text Block] Net Loss Per Common Share Statement Of Income And Comprehensive Income [Abstract] Statement [Line Items] Statement [Line Items] Security12b Title Title of 12(b) Security Common Stock [Member] Common Stock [Member] Net Cash Provided By Used In Operating Activities [Abstract] Cash flows from operating activities Equity Component [Domain] Equity Component Entity Address State Or Province Entity Address, State or Province Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Net (decrease) increase in cash and cash equivalents Document Type Document Type Entity Shell Company Entity Shell Company Summary of significant accounting policies. Summary Of Significant Accounting Policies [Line Items] Summary Of Significant Accounting Policies [Line Items] Allocated Share Based Compensation Expense Allocated share based compensation expense Asset sale agreement. Asset Sale Agreement [Member] Asset Sale Agreement [Member] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Security Exchange Name Security Exchange Name Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Significant Accounting Policies [Text Block] Summary of Significant Accounting Policies Net cash used in operating activities Net Cash Provided By Used In Operating Activities Cash used in operating activities Fair Value By Balance Sheet Grouping [Table] Fair Value By Balance Sheet Grouping [Table] Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and nonemployees. Allocated Share Based Compensation Expense Including Non Employees Stock-based compensation expense Upfront cash payment received. Upfront Cash Payment Received Upfront cash payment received New Accounting Pronouncements Policy Policy [Text Block] Recent Accounting Pronouncements Common Stock Shares Outstanding Common stock, shares outstanding Common Stock, Shares, Outstanding, Beginning Balance Common Stock, Shares, Outstanding, Ending Balance Fair Value Inputs Level2 [Member] Level 2 [Member] Net Cash Provided By Used In Investing Activities [Abstract] Cash flows from investing activities Carrying value as of the balance sheet date of obligations incurred through that date arising from ongoing clinical trial activity. Accrued Clinical Trial Costs Accrued clinical trial costs Commitments And Contingencies Commitments and contingencies Common Stock Shares Issued Common stock, shares issued Minimum [Member] Minimum [Member] Accrued Liabilities Current Accrued goods and services Accrued Liabilities, Current, Total Stockholders Equity [Abstract] Stockholders’ equity: Counterparty Name [Axis] Counterparty Name Entity Address Address Line2 Entity Address, Address Line Two Comparability Of Prior Year Financial Data Unaudited Interim Financial Information Aggregate intrinsic value of options exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Nonoperating Income Expense [Abstract] Other income: Entity Central Index Key Entity Central Index Key Accounting Policies [Abstract] Fair Value By Measurement Frequency [Axis] Measurement Frequency Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Shares of common stock available for grant (in shares) Pegascy SAS. Pegascy S A S [Member] Pegascy SAS [Member] Disclosure Of Compensation Related Costs Share Based Payments [Text Block] Stock-Based Compensation General And Administrative Expense General and administrative expenses General and Administrative Expense, Total Organization Consolidation And Presentation Of Financial Statements [Abstract] Adjustments to reconcile net loss to net cash used in operating activities Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Retained Earnings [Member] Accumulated Deficit [Member] Money Market Funds [Member] Money Market Funds [Member] Stock Incentive Plan 2021 [Member]. Stock Incentive Plan2021 [Member] Stock Incentive Plan 2021 [Member] Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] Transaction expenses. Transaction Expenses Transaction expenses Entity Interactive Data Current Entity Interactive Data Current Milestone achievement one member. Milestone Achievement One [Member] Achievement of the Primary Endpoint in the First Registrational Clinical Study of Either MM-121 or MM-111 [Member] Local Phone Number Local Phone Number Fair Value Assets Measured On Recurring Basis [Text Block] Summary of Assets Measured at Fair Value on a Recurring Basis Additional payments receivable on achievement of certain milestone events. Additional Payments Receivable On Achievement Of Certain Milestone Events Additional payments receivable on achievement of certain milestone events Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Basis Of Accounting Policy Policy [Text Block] Basis of Presentation Additional Indication [Member] Additional Indication [Member] Number of options granted Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Income Statement Location [Domain] Income Statement Location Shares Outstanding Balance (in shares) Balance (in shares) Increase Decrease In Prepaid Deferred Expense And Other Assets Prepaid expenses and other current assets Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Exercise period of option. Exercise Period Of Option Exercise period of option Document Fiscal Year Focus Document Fiscal Year Focus Earnings Per Share Basic Net loss per common share - basic Earnings Per Share, Basic, Total Assets [Abstract] Assets Prepaid Expense And Other Assets Current Prepaid expenses and other current assets Stock Compensation Plan [Member] Outstanding Options to Purchase Common Stock [Member] Number of posters on NRGI fusions Number of Posters on NRGI Fusions Number of posters on NRGI fusions Liabilities And Stockholders Equity [Abstract] Liabilities and stockholders’ equity Antidilutive Securities Name [Domain] Antidilutive Securities, Name Profit Loss Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total Assets Current [Abstract] Current assets: Fair Value Measurements Fair Value Hierarchy [Domain] Fair Value Hierarchy and NAV Payables And Accruals [Abstract] Fair Value Measurement Frequency [Domain] Measurement Frequency Increase Decrease In Operating Capital [Abstract] Changes in operating assets and liabilities: Entity [Domain] Entity Cover [Abstract] Accounting Changes And Error Corrections [Abstract] Liabilities Current [Abstract] Current liabilities: Maximum [Member] Maximum [Member] Net Cash Provided By Used In Investing Activities Net cash provided by investing activities Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Number of options exercised Stock Issued During Period Shares Stock Options Exercised Fair Value Inputs Level3 [Member] Level 3 [Member] Accounts Payable And Accrued Liabilities Current Accounts payable, accrued expenses and other Total accounts payable, accrued expenses and other Use Of Estimates Use of Estimates Stock Issued During Period Value Stock Options Exercised Exercise of stock options Common Stock Shares Authorized Common stock, shares authorized Trading Symbol Trading Symbol Amount of gain (loss) on payment of option fee. Gain Loss On Payment Of Option Fee Gain related to option fee payment Comprehensive Income Net Of Tax Net loss and comprehensive loss Net loss from continuing operations Accounts Payable Current Accounts payable Accounts Payable, Current, Total Increase (Decrease) in Other Operating Assets, Total Increase (Decrease) in Other Operating Assets Other assets Other assets Plan Name [Axis] Plan Name Common Stock Par Or Stated Value Per Share Common stock, par value Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price Weighted Average Exercise Price Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount Outstanding options to purchase common stock Cash And Cash Equivalents Fair Value Disclosure Cash equivalents